3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
17
pembrolizumab
16
Cisplatin
14
enfortumab vedotin
7
avelumab
7
Nivolumab
6
Docetaxel
6
atezolizumab
5
Paclitaxel
5
Cystectomy
5
sacituzumab govitecan
4
durvalumab
4
Mitomycin
4
Cystoscopy
4
Carboplatin
4
vofatamab
3
tremelimumab
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
vinflunine
2
tisotumab vedotin
2
poly ICLC
2
cemiplimab
2
aldesleukin
2
Transurethral Resection of Bladder
2
Radiotherapy, Intensity-Modulated
2
Ipilimumab
2
Interleukin-2
2
Immunoglobulin G
2
Clinical Trials, Phase II as Topic
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Urinary Bladder Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled